Emmanuelle di Tomaso,Marie-Caroline Germa,Cristian Massacesi,Christine Fritsch,Christian René Schnell,Ranjana Tavorath
申请号：
US15719636
公开号：
US20180078540A1
申请日:
2017.09.29
申请国别(地区):
US
年份:
2018
代理人:
摘要：
The present invention relates to methods of treating or preventing a proliferative disease in a patient in need thereof by orally administering a therapeutically effective amount of an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor compound of formula (I) or a pharmaceutically acceptable salt thereof for at least two five-consecutive day cycle, wherein said compound is not administered to the patient for a period of about two days to about three days between said five-consecutive day cycles the use of said compound of formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating or preventing a proliferative disease administered in accordance with said dosage regimen therapeutic regimen comprising administration of said compound of formula (I) or a pharmaceutically acceptable salt thereof in accordance with said dosage regimen and related pharmaceutical compositions and packages thereof.
